Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takeo Iwama is active.

Publication


Featured researches published by Takeo Iwama.


Oncogene | 1999

Higher frequency of smad4 gene mutation in human colorectal cancer with distant metastasis

Michiko Miyaki; Takeru Iijima; Motoko Konishi; Kimiyo Sakai; Aki Ishii; Masamichi Yasuno; Tsunekazu Hishima; Morio Koike; Nobuyuki Shitara; Takeo Iwama; Toshio Kuroki; Takeo Mori

We have previously detected an increased frequency of loss of heterozygosity (LOH) on chromosome 18q during progression of colorectal carcinomas. To clarify the target of 18qLOH, mutation of Smad4 and Smad2 genes was analysed in 176 colorectal tumors with different stages, including liver metastasis, from 111 sporadic, 52 familial adenomatous polyposis (FAP) and nine hereditary nonpolyposis colorectal cancer (HNPCC) patients. Mutation of other Smad gene families in the TGF-β signaling pathway was also examined. Twenty-one Smad4 mutations and one Smad2 mutation were detected, whereas mutation of Smad3, 6 and 7 genes was not detected. Smad4 mutations included seven frameshift, one inframe deletion, four nonsense and nine missense mutations, 95% of which resulted in alteration of Smad4 protein regions included in homo-oligomer and hetero-oligomer formation. Frequencies of tumors with Smad4 mutation were 0/40 (0%) in adenoma, 4/39 (10%) in intramucosal carcinoma, 3/44 (7%) in primary invasive carcinoma without distant metastasis, 6/17 (35%) in primary invasive carcinoma with distant metastasis, and 11/36 (31%) in distant metastasis (metastatic/non-metastatic: P=0.006 ∼0.01). Loss of the other allele was observed in 19 of 20 (95%) invasive and metastasized carcinomas with Smad4 mutations. In four cases both primary and metastasized carcinomas in the same patients showed the same mutations. The present results suggest that Smad4 gene is one of true targets of 18qLOH, and that its inactivation is involved in advanced stages, such as distant metastasis, in human colorectal carcinogenesis.


Gut | 2000

Analysis of genetic and phenotypic heterogeneity in juvenile polyposis

Kelly Woodford-Richens; S Bevan; Michael Churchman; B Dowling; Daniel Jones; C. G. Norbury; Shirley Hodgson; D Desai; Kay Neale; Robin K. S. Phillips; Joanne Young; Barbara A. Leggett; Malcolm G. Dunlop; Paul Rozen; Charis Eng; David Markie; Miguel A. Rodriguez-Bigas; Eamonn Sheridan; Takeo Iwama; Diana Eccles; Gregory T. Smith; Jin Cheon Kim; Kang Mo Kim; Julian Roy Sampson; G Evans; Sabine Tejpar; Walter F. Bodmer; I P M Tomlinson; Richard S. Houlston

BACKGROUND Juvenile polyposis syndrome (JPS) is characterised by gastrointestinal (GI) hamartomatous polyposis and an increased risk of GI malignancy. Juvenile polyps also occur in the Cowden (CS), Bannayan-Ruvalcaba-Riley (BRRS) and Gorlin (GS) syndromes. Diagnosing JPS can be problematic because it relies on exclusion of CS, BRRS, and GS. Germline mutations in the PTCH, PTENand DPC4 (SMAD4)genes can cause GS, CS/BRRS, and JPS, respectively. AIMS To examine the contribution of mutations in PTCH,PTEN, and DPC4(SMAD4) to JPS. METHODS Forty seven individuals from 15 families and nine apparently sporadic cases with JPS were screened for germline mutations inDPC4, PTEN, andPTCH. RESULTS No patient had a mutation in PTEN orPTCH. Five different germline mutations were detected in DPC4; three of these were deletions, one a single base substitution creating a stop codon, and one a missense change. None of these patients had distinguishing clinical features. CONCLUSIONS Mutations in PTEN and PTCHare unlikely to cause juvenile polyposis in the absence of clinical features indicative of CS, BRRS, or GS. A proportion of JPS patients harbour DPC4 mutations (21% in this study) but there remains uncharacterised genetic heterogeneity in JPS.


Journal of Medical Genetics | 1998

Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3.

Sylviane Olschwang; David Markie; S Seal; Kay Neale; R. K. S. Phillips; Sally E. Cottrell; I Ellis; Shirley Hodgson; Peter Zauber; Allan D. Spigelman; Takeo Iwama; S Loff; Colina McKeown; C Marchese; Julian Roy Sampson; S Davies; I. C. Talbot; J Wyke; Gilles Thomas; Walter F. Bodmer; Akseli Hemminki; Egle Avizienyte; A. de la Chapelle; Lauri A. Aaltonen; I Tomlinson

A locus for Peutz-Jeghers syndrome (PJS) was recently mapped to chromosome 19p13.3. Each of 12 families studied was compatible with linkage to the marker D19S886. We have analysed 20 further families and found that the majority of these are consistent with a PJS gene on 19p13.3. Three families were, however, unlinked to 19p13.3 and none of the available PJS polyps from these families showed allele loss at D19S886. There were no obvious clinicopathological or ethnic differences between the 19p13.3 linked and unlinked families. There appears, therefore, to be a major PJS locus on chromosome 19p13.3 and the possibility exists of a minor locus (or loci) elsewhere.


Gut | 1999

Screening SMAD1 , SMAD2 , SMAD3 , and SMAD5 for germline mutations in juvenile polyposis syndrome

S Bevan; Kelly Woodford-Richens; Paul Rozen; Charis Eng; Joanne Young; Malcolm G. Dunlop; Kay Neale; Robin K. S. Phillips; David Markie; Miguel A. Rodriguez-Bigas; Barbara A. Leggett; Eammon Sheridan; Shirley Hodgson; Takeo Iwama; Diana Eccles; Walter F. Bodmer; Richard S. Houlston; Ian Tomlinson

BACKGROUND AND AIMS Juvenile polyps occur in several Mendelian disorders, whether in association with gastrointestinal cancer alone (juvenile polyposis syndrome, JPS) or as part of known syndromes (Cowden, Gorlin, and Bannayan-Zonana) in association with developmental abnormalities, dysmorphic features, or extraintestinal tumours. Recently, some JPS families were shown to harbour germline mutations in theSMAD4 (DPC4) gene, providing further evidence for the importance of the TGFβ signalling pathway in colorectal cancer. There remains, however, considerable, unexplained genetic heterogeneity in JPS. Other members of the SMAD family are excellent candidates for JPS, especiallySMAD2 (which, likeSMAD4, is mutated somatically in colorectal cancers), SMAD3 (which causes colorectal cancer when “knocked out” in mice),SMAD5, and SMAD1. METHODS SMAD1,SMAD2, SMAD3, andSMAD5 were screened for germline mutations in 30 patients with JPS and without SMAD4mutations. RESULTS No mutations were found in any of these genes. A G–A C89Y polymorphism with possible effects on protein function was found in SMAD3, but the frequencies of the G and A alleles did not differ between patients with JPS and controls. CONCLUSIONS It remains to be determined whether or not this polymorphism is involved in a minor predisposition to colorectal or other carcinomas.SMAD4 may be the only member of the SMAD family which causes JPS when mutant in the germline. The other genes underlying JPS remain to be identified.


International Journal of Clinical Oncology | 2004

A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan

Takeo Iwama; Kazuo Tamura; Takayuki Morita; Takashi Hirai; Hirotoshi Hasegawa; Koichi Koizumi; Kenichi Sugihara; Takehira Yamamura; Tetsuichiro Muto; Joji Utsunomiya; Rectum

The clinical situation of familial adenomatous polyposis (FAP) in Japan has changed in the period since the last analysis of data of the Japanese Polyposis Center. To reevaluate our data and elucidate the changes we analyzed the records of the 1390 FAP patients in 900 families registered with the Polyposis Committee of the Japanese Society for Cancer of the Colon and Rectum. In the 13-year period 1990–2003, clinical differences between men and women with FAP diminished. The postoperative prognosis was substantially better in patients without advanced colorectal cancer (stage ≧ T2) than in those with early cancer or no cancer. Mean age at death improved from 42.5 years in the period before 1990 to 46.0 years, and it was a result of a decreased proportion of deaths from colorectal cancer. The distribution of colorectal cancer in FAP patients was similar to that in the general population. Desmoid tumors accounted for about 10% of deaths in the recent 13 years (1990–2003). The cumulative risk of rectal cancer in the preserved rectum was 12% at 10 years and 23% at 15 years. The registry system in Japan revealed a new clinical situation in FAP patients, and the findings of this study will be useful to improve the prognosis of patients with FAP.


Diseases of The Colon & Rectum | 2000

Development of invasive adenocarcinoma in a long-standing diverted ileal J-pouch for ulcerative colitis : Report of a case

Takeo Iwama; Jiro Kamikawa; Tetsuro Higuchi; Kazuo Yagi; Tadashi Matsuzaki; Jun Kanno; Akihiko Maekawa

We report a case of a 50-year-old male with ulcerative colitis who developed well-differentiated adenocarcinoma in the ileal J-pouch, which had been defunctioning for 18 years. The extension of the carcinoma in the pouch suggested that it had recently appeared in the pouch. Monitoring by endoscopic examination and biopsy or pouch excision seems to be an appropriate action if a pouch is out of the fecal stream.


American Journal of Pathology | 2000

Molecular evidence for multicentric development of thyroid carcinomas in patients with familial adenomatous polyposis.

Michiko Miyaki; Takeru Iijima; Reiko Ishii; Tsunekazu Hishima; Takeo Mori; Keigo Yoshinaga; Hiroshi Takami; Toshio Kuroki; Takeo Iwama

Familial adenomatous polyposis is characterized by multiple colorectal adenomas and an increased incidence of colorectal carcinomas. Patients also develop various extracolonic tumors, of which, thyroid carcinoma is common in young females. The occurrence of multiple carcinomas in one thyroid is frequently observed, although some carcinomas are solitary. To clarify whether each carcinoma develops independently or metastatically spreads from the first one formed, we analyzed the adenomatous polyposis coli (APC) gene mutation in each carcinoma. We found that each carcinoma had a different somatic mutation of the APC gene. This is molecular confirmation for the multicentric development of thyroid carcinomas in familial adenomatous polyposis through biallelic inactivation of the APC gene.


Japanese Journal of Cancer Research | 1999

Somatic Mutation of the APC Gene in Thyroid Carcinoma Associated with Familial Adenomatous Polyposis

Takeo Iwama; Motoko Konishi; Takeru Iijima; Keigo Yoshinaga; Takeshi Tominaga; Morio Koike; Michiko Miyaki

We report the existence of both germline and somatic mutations of the APC gene in thyroid carcinomas from familial adenomatous polyposis (FAP) patients. One papillary thyroid carcinoma from a 20‐year‐old woman, with germline mutation of the APC gene (TCA to TGA at codon 1110), showed a somatic mutation of AAAAC deletion between codons 1060 and 1063. Another somatic mutation of CAG to TAG at codon 886 was also found in one of multiple thyroid carcinomas from a 26‐year‐old woman with attenuated FAP and germline mutation at codon 175 (C deletion). This is the first evidence that total absence of the normal function of the APC gene is involved in development of thyroid carcinomas in FAP.


Surgery Today | 2003

Intratumoral heterogeneity of genetic changes in primary colorectal carcinomas with metastasis.

Hiroyuki Fukunari; Takeo Iwama; Kenichi Sugihara; Michiko Miyaki

AbstractPurpose. To elucidate the intratumoral distribution of genetic changes, surgically resected colorectal carcinomas were investigated regarding their loss of heterozygosity in the regions of tumor suppressor genes and the mutation of ras genes. Methods. Full-thickness fresh tumor slices from 23 colorectal carcinomas were removed and divided into multiple specimens, which were then submitted separately for DNA and histopathological analyses. The loss of heterozygosity was analyzed in 23 primary carcinomas and 9 metastasized carcinomas by the use of restriction fragment-length polymorphism markers on chromosome 1p, 5q, 17p, 18q, and 22q. Results. Intratumoral heterogeneity was identified in 11 of 23 primary carcinomas (47.8%) and we could successfully map the regional genetic variation. In both stages I and II, 1 of 5 cases (20%); in stage III, 3 of 6 cases (50%); and in stage IV, 6 of 7 cases (85.7%) were heterogeneous. With respect to venous invasion positive primary carcinomas, hepatic metastasis occurred in 75% (6/8) of the heterogeneous carcinomas, whereas hepatic metastasis occurred in only 12.5% (1/8) of homogeneous carcinomas. Conclusion. The present results suggest that the existence of intratumoral heterogeneity, which may reflect genetic instability, may thus play a role in the enhancement of aggressive progression and the metastasis of colorectal carcimomas.


International Journal of Clinical Oncology | 2006

Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial

Takeo Iwama; Takayuki Akasu; Tetsuichiro Muto

BackgroundThere have been few placebo-controlled randomized double-blind studies of the clinical effects of selective cyclooxygenase-2 (COX-2) inhibitors on the regression of colorectal tumors. This study was designed to examine the regressive effect of a selective COX-2 inhibitor, tiracoxib (JTE-522), on colorectal polyps in patients with familial adenomatous polyposis (FAP), and its safety.MethodsSixty-one patients with FAP diagnosed by Japanese criteria were assigned randomly to receive placebo or JTE-522, at either 150 mg or 200 mg, once daily orally for 26 weeks. Prior to and at the end of the medication period, endoscopy was performed. Adenomas located near an india-ink tattoo injected at the first colonoscopy were identified and measured. The response variables were the percent changes from the baseline in polyp numbers and in specified polyp diameters. Any adverse events that appeared in at least four persons were taken into consideration and compared between the JTE-522 treatment groups and the placebo group.ResultsNo change in polyp number (median, 0) was observed in any of the three groups. There were no differences between the placebo group and the two treatment groups in the change in polyp size. JTE-522 was well tolerated.ConclusionOur findings, in keeping with other reports on COX-2 inhibitors, indicated that the inhibition of a COX-2 with a moderate dose of a selective COX-2 inhibitor did not induce clinically sufficient regression of adenomas in patients with FAP in a limited (6-month) medication period.

Collaboration


Dive into the Takeo Iwama's collaboration.

Top Co-Authors

Avatar

Yoshio Mishima

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hideyuki Ishida

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Joji Utsunomiya

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Keigo Yoshinaga

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar

Kenichi Sugihara

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar

Mahito Imajo

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kay Neale

Imperial College London

View shared research outputs
Researchain Logo
Decentralizing Knowledge